We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lipid Profiling of Blood Samples Reveals Biomarkers for Cardiometabolic Disease Risk

By LabMedica International staff writers
Posted on 29 Apr 2022

A lipidomics-based analysis of plasma samples from a large cohort of participants identified several lipids associated with cardiometabolic disease risk that might serve as biomarkers for diagnosis of cardiovascular disease and Type II diabetes. More...

Lipidomics is the large-scale study of pathways and networks of cellular lipids in biological systems. The word "lipidome" is used to describe the complete lipid profile within a cell, tissue, organism, or ecosystem and is a subset of the "metabolome" which also includes the three other major classes of biological molecules: proteins/amino-acids, sugars, and nucleic acids. Lipidomics is a relatively recent research field that has been driven by rapid advances in technologies such as mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, dual polarization interferometry, and computational methods coupled with the recognition of the role of lipids in many metabolic diseases such as obesity, atherosclerosis, stroke, hypertension, and diabetes.

Cardiovascular disease is the leading cause of death worldwide, accounting for around 18 million deaths per year. People with Type II diabetes have a two- to threefold increased risk of suffering a heart attack or stroke. Accordingly, there is a great need to identify biomarkers that can indicate the development of disease at an early stage in order to prevent or at least mitigate its onset.

In this regard, investigators at the German Institute of Human Nutrition (DifE) of the German Center for Diabetes Research (Deutsches Zentrum fuer Diabetesforschung) evaluated the fatty acid profiles in 2,414 blood samples from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. The samples were collected as early as the 1990s and in part came from participants who developed cardiovascular disease or Type II diabetes in subsequent years.

Using high-throughput lipidomics, the investigators identified a total of 282 different lipids, 69 of which were associated with at least one of the two diseases. Several monoacylglycerols and 16 and 18 chain fatty acids in diacylglycerols were associated with both outcomes. Cholesteryl esters, free fatty acids, and sphingolipids were largely cardiovascular disease-specific, while several (glycero)phospholipids were Type II diabetes-specific.

First author Dr. Fabian Eichelmann, a researcher in the department of molecular epidemiology at the German Institute of Human Nutrition and at the German Center for Diabetes Research, said, "A statistical association with cardiovascular diseases was found for 49 lipids, which mainly belonged to the cholesterol esters and sphingolipids. Twelve lipids were associated with Type II diabetes, the majority of which were glycerol and phospholipids. An association with both diseases was seen for eight lipids, among which several monoacylglycerides stood out."

The study was published in the April 15, 2022, online edition of the journal Circulation.

Related Links:
German Institute of Human Nutrition 
German Center for Diabetes Research 

 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.